Park Ki Cheong, Choi Seung Hoon
Brain Korea 21 Project for Medical Science, Yonsei University College of Medicine, 134 Shinchon-dong, Seodaemun-gu, Seoul, 120-752, Korea.
Pediatr Surg Int. 2013 Dec;29(12):1327-40. doi: 10.1007/s00383-013-3398-1.
New development in the vascular network is a significant process for the proliferation, as well as metastatic expand, of cancer cells that depends on a sufficient provider of oxygen and nutrients and the removal of waste products. New blood and lymphatic vessels form via step called angiogenesis and lymphangiogenesis. Angiogenesis is controlled by activator and inhibitor of some molecules. So many different proteins have been established as angiogenic activators and inhibitors. Grades of expression of angiogenic factors demonstrate the forcefulness of tumor cells. The advance of angiogenic inhibitors should help to decrease both mortality and morbidity from carcinomas. So many patients have received anti-angiogenic therapy to date. Nevertheless, their notional efficacy and anti-angiogenic treatments have not demonstrated to be useful in terms of long-term survival. There is a crucial need for a new close treatment plan combining anti-angiogenic agents with standard cyto-reductive treatments in the regulation of cancer.
血管网络的新发展对于癌细胞的增殖以及转移性扩散来说是一个重要过程，这依赖于充足的氧气和营养物质供应以及废物的清除。新的血管和淋巴管通过称为血管生成和淋巴管生成的步骤形成。血管生成由某些分子的激活剂和抑制剂控制。因此，许多不同的蛋白质已被确定为血管生成激活剂和抑制剂。血管生成因子的表达水平表明肿瘤细胞的活跃程度。血管生成抑制剂的进展应有助于降低癌症的死亡率和发病率。到目前为止，已有许多患者接受了抗血管生成治疗。然而，它们的理论疗效和抗血管生成治疗在长期生存方面尚未被证明是有效的。在癌症治疗中，迫切需要一种将抗血管生成药物与标准细胞减灭治疗相结合的新的综合治疗方案。
